A FormBlends network publication
FormBlends Video Library

Playlist: Obesity science and outcomes

Three short Yale Medicine explainers on the set point, medication and lifestyle, then two hour-long clinical lectures from Stanford Health Care and UCSF that walk through the trials number by number.

By FormBlends editorial teamUpdated September 4, 2026Educational, not medical advice

Playlist player

Open full calculator

Obesity science and outcomes: 5 videos, about 133 minutes in total. Watch in order; each write-up assumes the ones before it.

  1. 1 of 5 · 4:26

    How Obesity Medicine Works - Yale Medicine Explains

    Yale Medicine · Original

    A Yale physician explains the defended fat-mass set point: obesity as a neurometabolic disease, why lifestyle loss is hard to hold, how nutrient-stimulated hormones inform the brain, and why medications and surgery work by acting on the mechanism rather than on willpower.

    Read the full fact-check

  2. 2 of 5 · 3:15

    Medical Therapies for Weight Management - Yale Medicine Explains

    Yale Medicine · Original

    Yale clinicians on where medication fits: the set point again, incretin-based drugs imitating fullness hormones, the fact that every trial paired the drug with a calorie deficit and activity, the wide range of individual response, and combining medication with endoscopic procedures.

    Read the full fact-check

  3. 3 of 5 · 3:56

    Lifestyle Interventions for Weight Management - Yale Medicine Explains

    Yale Medicine · Original

    Yale's weight management team on lifestyle: intervention alone averages about 3 to 4 percent loss, diet means eating pattern rather than restriction, exercise is weaker for weight loss than medication or surgery but essential for maintenance and health, and sleep and mood matter.

    Read the full fact-check

  4. 4 of 5 · 59:23

    GLP-1 Receptor Agonists: The Truth Behind the Trend

    Stanford Health Care · Original

    A Stanford Health Care clinical pharmacist's hour-long walk through the evidence: GLP-1 physiology, each agent and its dose steps, A1c and weight results from SUSTAIN, SUSTAIN FORTE, SURPASS and SURMOUNT, the SUSTAIN-6 and FLOW outcome trials, and the retinopathy caution with rapid glucose lowering.

    Read the full fact-check

  5. 5 of 5 · 1:01:36

    Beyond the Scale: Harnessing Anti-Obesity Medications to Treat Obesity and its Complications

    UCSF Department of Medicine · Original

    UCSF Department of Medicine grand rounds from the director of the UCSF weight management clinic: what percentage of loss improves which comorbidity, every FDA-approved anti-obesity medication with its one-year and two-year figures, GLP-1 pharmacology, side-effect rates, and the observation that women respond more strongly to tirzepatide in the SURMOUNT trials.

    Read the full fact-check

Watch order and why

The three Yale videos take about ten minutes together and give the frame: obesity as a defended set point, medication as one part of a program with wide individual variation, and lifestyle as essential for health but modest for weight loss on its own. Then choose a lecture. Stanford Health Care's clinical pharmacist approaches from the diabetes side, trial by trial. UCSF's grand rounds approaches from the obesity side, agent by agent, with one-year and two-year figures and the responder distributions. Each fact-check lists the figures quoted loosely and gives the published ones.

Numbers to carry with you

Lifestyle in a trial-intensity program: 8.6 percent at one year and 6.2 percent at four in Look AHEAD (PubMed 20876408). Semaglutide 2.4 mg: 14.9 percent at 68 weeks, with 32 percent of participants losing 20 percent or more (PubMed 33567185). Tirzepatide 15 mg: 20.9 percent at 72 weeks, with 36 percent losing 25 percent or more (PubMed 35658024). Placebo arms with lifestyle counselling: 2.4 and 3.1 percent.

What the playlist does not settle

Whether the set point is reset or merely overridden, who will respond, and how much lean mass is lost are open questions that every honest lecture in this playlist flags. For the mechanism pages, FormBlends Science; for trial digests with confidence intervals, FormBlends Research; for protein, training and a plateau check against the trial curves, Weight Loss on GLP-1s. FormBlends' compounded products at formblends.com are not FDA approved and were not in any trial named here.

Sources

  1. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021. PubMed 33567185 Accessed September 4, 2026.
  2. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 2022. PubMed 35658024 Accessed September 4, 2026.
  3. Look AHEAD Research Group. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in type 2 diabetes: four-year results. Arch Intern Med 2010. PubMed 20876408 Accessed September 4, 2026.

Canonical URL: https://formblendsvideos.com/playlists/obesity-science-and-outcomes. Written by the FormBlends editorial team. This page is educational and is not medical advice; see the medical disclaimer.